Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.
Br J Haematol. 2006 Apr;133(2):141-51. doi: 10.1111/j.1365-2141.2005.05869.x.
Br J Haematol. 2006.
PMID: 16611304
Free article.
A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.
Schwemmlein M, Stieglmaier J, Kellner C, Peipp M, Saul D, Oduncu F, Emmerich B, Stockmeyer B, Lang P, Beck JD, Fey GH.
Schwemmlein M, et al.
Leukemia. 2007 Jul;21(7):1405-12. doi: 10.1038/sj.leu.2404687. Epub 2007 May 10.
Leukemia. 2007.
PMID: 17495978
Item in Clipboard
A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.
Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kügler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dörrie J, Ferrone S, Kämpgen E, Fey GH.
Schwenkert M, et al. Among authors: schwemmlein m.
Melanoma Res. 2008 Apr;18(2):73-84. doi: 10.1097/CMR.0b013e3282f7c8f9.
Melanoma Res. 2008.
PMID: 18337643
Free PMC article.
Item in Clipboard
Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F, Schwemmlein M, Stein C, Mentz K, Mackensen A, Fey GH.
Singer H, et al. Among authors: schwemmlein m.
J Immunother. 2010 Jul-Aug;33(6):599-608. doi: 10.1097/CJI.0b013e3181dda225.
J Immunother. 2010.
PMID: 20551837
Item in Clipboard
A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH.
Kellner C, et al. Among authors: schwemmlein m.
J Immunother. 2008 Nov-Dec;31(9):871-84. doi: 10.1097/CJI.0b013e318186c8b4.
J Immunother. 2008.
PMID: 18833000
Item in Clipboard
Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems.
Rothdiener M, Müller D, Castro PG, Scholz A, Schwemmlein M, Fey G, Heidenreich O, Kontermann RE.
Rothdiener M, et al. Among authors: schwemmlein m.
J Control Release. 2010 Jun 1;144(2):251-8. doi: 10.1016/j.jconrel.2010.02.020. Epub 2010 Feb 22.
J Control Release. 2010.
PMID: 20184933
Item in Clipboard
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W.
ten Cate B, et al. Among authors: schwemmlein m.
Leukemia. 2009 Aug;23(8):1389-97. doi: 10.1038/leu.2009.34. Epub 2009 Mar 5.
Leukemia. 2009.
PMID: 19262596
Item in Clipboard
Cite
Cite